New stem cell approach aims to improve survival in blood cancer patients
NCT ID NCT07493538
First seen Apr 05, 2026 · Last updated Jun 08, 2026 · Updated 12 times
Summary
This study is for people with blood cancers like AML or MDS. It tests a stem cell transplant using a milder chemo combination (treosulfan and fludarabine) followed by drugs to prevent graft-versus-host disease. The goal is to see if this approach improves survival at 100 days and beyond. Participants must be 2-75 years old and have a suitable donor.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Masonic Cancer Center at University of Minnesota
RECRUITINGMinneapolis, Minnesota, 55455, United States
Conditions
Explore the condition pages connected to this study.